Maxwell Prempeh, MD
Interventional Cardiology · Cartersville, GANPI 1992867592
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $32,740 of the $46,735 with a category attached, or 70.1%. Actelion Pharmaceuticals US, Inc. accounts for 75.0% of it on its own, with 42 other manufacturers making up the rest. Reporting peaked in 2023 at $12,667 and has fallen 90.7% since, to $1,182 in 2025.
Across 521 payments — averaging $89.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$35K
- Abbott$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
- Johnson & Johnson$1K
- Novartis$596
- AstraZeneca$577
- plus $6K from 37 others
What the payments were for
- Speaking & faculty fees$32,74070%
- Travel & lodging$1,3863%
- Food & beverage$12,27426%
- Education$3351%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$25,665
- OPSUMIT$25,655
- OPTIS$871
- Barostim Neo System$320
- XARELTO$245
- FLOWTRIEVER CATHETER, S$171
- CT THROMBECTOMY SYSTEM KIT$171
- Indigo System$158
- Repatha$132
- Inpefa$122
- LOKELMA$121
- FFRct$119
- FARXIGA$118
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$115
- XIENCE SKYPOINT$111
- PARADISE RENAL DENERVATION SYSTEM$103
How this compares
$46,735 in reported general payments places this provider in the 85th percentile of 218 interventional cardiology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 50 | $627,810 |
| EliquisApixaban | 433 | $457,324 |
| AdempasRiociguat | 20 | $283,110 |
| EntrestoSacubitril/Valsartan | 119 | $161,785 |
| XareltoRivaroxaban | 83 | $113,880 |
| BrilintaTicagrelor | 102 | $85,789 |
| FarxigaDapagliflozin Propanediol | 38 | $56,384 |
| MultaqDronedarone Hcl | 24 | $47,569 |
| Repatha SureclickEvolocumab | 47 | $37,892 |
| KerendiaFinerenone | 16 | $29,533 |
| VascepaIcosapent Ethyl | 29 | $20,399 |
| Praluent PenAlirocumab | 20 | $16,494 |
| NexlizetBempedoic Acid/Ezetimibe | 13 | $12,749 |
| JardianceEmpagliflozin | 16 | $10,696 |
| Ranolazine ErRanolazine | 65 | $7,265 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $35,063 | $627,81050 claims |
| PfizerEliquis | $315 | $457,324433 claims |
| BayerAdempas, Kerendia | $387 | $312,64336 claims |
| NovartisEntresto | $596 | $161,785119 claims |
| AstraZenecaBrilinta, Farxiga | $577 | $142,173140 claims |
| Johnson & JohnsonXarelto | $1,088 | $113,88083 claims |
| Sanofi-aventis U.S. LLCMultaq | $102 | $47,56924 claims |
| Esperion Therapeutics, Inc.Nexlizet | $84 | $12,74913 claims |
| Boehringer IngelheimJardiance | $53 | $10,69616 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $287 | $7,16812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 218 interventional cardiology providers in Georgia.
Other interventional cardiology in Cartersville
- William NicholsonAtlanta$1000K
- David KandzariAtlanta$982K
- Pradeep YadavAtlanta$656K
- Salvatore ManninoMarietta$275K
- Megan CoylewrightCalhoun$271K
- Paul GuichardMarietta$260K
- Adam GreenbaumAtlanta$238K
- Wissam JaberAtlanta$222K
- Mudassar AhmedGainesville$193K
- Katherine KunkelAtlanta$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.